- First-half revenue up 10.4% year over year; operating profit up 24.5% year over year
- Second-quarter (separate basis) revenue of KRW 384.0 billion; operating profit of KRW 25.1 billion
SK Chemicals announced on the 7th that, on a separate (parent-only) basis, it posted first-half revenue of KRW 731.1 billion and operating profit of KRW 62.1 billion.
Compared with the same period last year, revenue rose 10.4%, while operating profit increased 24.5%.
By quarter, second-quarter revenue came to KRW 384.0 billion, up 11.4% year over year, and operating profit was KRW 25.1 billion, down 19.6% year over year. The Pharma division benefited from growth in its in-licensed portfolio, including products from Viatris, which supported top-line expansion.
A company spokesperson said, “Even amid rising macro uncertainties, we worked to drive sales of our core products, including ECOZEN, although higher SG&A and other costs were reflected in the results. While the industry is expected to remain soft, we will pursue earnings improvement by expanding sales of high-value products and strengthening fundamental competitiveness through Operation Improvement (OI).”
On a consolidated basis including subsidiary SK bioscience, SK Chemicals reported first-half revenue of KRW 1,133.5 billion and operating profit of KRW 23.3 billion.
[Photo: Eco Lab, SK Chemicals headquarters in Pangyo, Seongnam, Gyeonggi-do, Korea]